Skip to main content Back to Top
Advertisement

6/13/2019

C1-Esterase Inhibitor (Human) Injection

Reason for the Shortage

    • CSL Behring has Berinert available. The company is shipping weekly to distributors.
    • Shire has resumed manufacturing and Cinryze is available.
    • The subcutaneous dosage form of C1-esterase inhibitor (human) is unaffected by this shortage.

Available Products

    • Berinert intravenous injection, CSL Behring, 500 unit, preservative-free vial, NDC 63833-0825-02
    • Cinryze intravenous injection, Shire, 500 unit, preservative-free vial, NDC 42227-0081-05

Implications for Patient Care

    • The following lots require filtering prior to administering: 17F19L37OA, 17F24L370A, 17G10L370A, 17G16L370A, 17G21L370A, 17H12L370A, 17G26L370A and 17H22L370A. Additional information and self-administration instructions are available at www.cinryze.com.

Updated

Updated June 13, 2019 by Anthony Trovato, PharmD, BCPS. Created August 16, 2017 by Benjamin Witt, PharmD, BCPS, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins